Renbase

The prevalence of chronic kidney disease is increasing. In the US, 13.9% of the adult population are estimated to have renal failure to some degree (1). Renal failure is recognised as a major risk factor for adverse drug reactions, particularly those related to altered drug excretion. Severe renal failure increases the risk of serious adverse drug reaction by more than 80%, compared to less severe renal failure or normal renal function (2).

Adverse drug reactions also constitute a major cause for hospitalisation in patients with chronic kidney disease (3). Approximately one-third of adverse drug reactions attributed to renal failure are considered preventable (2,3). Multiple aspects of drug therapy should be considered when treating patients with renal failure.

80%
“Severe renal failure increases the risk of serious adverse drug reaction by more than 80%.“

Classification methodology

Classification of renal failure

In Renbase, the degree of renal failure, based on glomerular filtration rate (GFR), is divided into four categories, according to the classification by the Europan Medicines Agency (EMA):

GFR 60- <90 ml/min	Mild renal failure
GFR 30- <60 ml/min	Moderate renal failure
GFR 15- <30 ml/min	Severe renal failure
GFR <15 ml/min	End-stage renal failure; dialysis patient

Classification of dosing recommendations

The safety and need for dosage modifications are classified into four categories (A–D), clarified by a traffic light-like system:

D	The use should be avoided

C	Modification of the dose or dosing interval is needed

B	The information is not available, or the recommendation is estimated based on the pharmacologic characteristics of the substance

A	No need for dosing modification

Languages and local drug registries

Medbase content is available in English and more than ten additional languages. To further improve local usability, we accommodate national, local and customer-specific drug product registries, allowing access to information using local drug product names and IDs.

Integration with local electronic health record (EHR) systems is straightforward, enabling smooth and efficient use of regularly updated Medbase drug information across various countries.

Latest information from trusted sources

All information is based on scientific evidence. We refer to published, peer-reviewed research articles from PubMed, a reliable source of biomedical and life sciences literature, as well as regulatory authority approved documents, such as the Summaries of Product Characteristics (SPC) of drugs.

Medbase Knowledgebase is continuously updated to ensure the inclusion of the latest information.

Supporting informed decisions for safe drug use

Enhanced patient safety

Holistic approach to patient’s pharmacotherapy enabling individualised drug treatment.

100% Evidence-based

Fully referenced information with transparency to original sources: documents approved by regulatory authorities and peer-reviewed literature.

Clinical relevance

We provide comprehensive and concise information for safe use of drugs, accessible from one single source.

Digitalised doctor consultation

Designed to support busy clinical practice for safe use of drugs. All information is created and validated by physicians specialised in clinical pharmacology.

“In the face of compromised kidneys, adjusting medication is key. Dosing strategies informed by renal function ensure optimal treatment while minimising risks.”

Renbase

Drug use and dosage in renal failure

Clinical solution

Key characteristics
of Renbase